Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications

被引:32
|
作者
Hicks, Angel Mier [1 ]
Chou, Joanne [2 ]
Capanu, Marinela [2 ]
Lowery, Maeve A. [3 ]
Yu, Kenneth H. [3 ]
O'Reilly, Eileen M. [3 ]
机构
[1] Icahn Sch Med Mt Sinai, Dept Med, St Lukes Roosevelt Hosp Ctr Program, New York, NY 10029 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
关键词
Denver shunt; Malignant ascites; Performance status; Peritoneal catheter; Teneckoff catheter; QUALITY-OF-LIFE; MALIGNANT ASCITES; PERITONEOVENOUS SHUNTS; PROGNOSTIC-FACTORS; CANCER; DIAGNOSIS; CATHETER; PATHOPHYSIOLOGY; CATUMAXOMAB; PALLIATION;
D O I
10.1016/j.clcc.2016.04.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This was a cohort analysis evaluating patients with pancreatic adenocarcinoma who presented with or developed ascites. Among the 180 patients analyzed, the use of serial paracenteses and indwelling catheters is a common practice to effect symptom palliation. The complication rate was higher in patients with indwelling catheters. Analyzing ascitic fluid and calculating the serum ascites albumin gradient can help attribute the etiology of the ascites and potentially identify which patients may benefit from diuretics or other intervention. Background: Ascites develops in a subset of patients with pancreatic adenocarcinoma (PAC) at presentation or as the disease advances. Limited data exist on the prognostic importance of malignant ascites in PAC. Our hypothesis is that this information will provide an understanding of the natural history and facilitate management decisions. Methods: We conducted a retrospective analysis of 180 patients treated at Memorial Sloan Kettering Cancer Center diagnosed between January 1, 2009 and December 31, 2014, with PAC and with ascites either at presentation or that developed during the disease course. Results: For the 180 patients, the overall survival was 15 months. The time from diagnosis to ascites presentation was 11 months, and the survival time after ascites development was 1.8 months (range, 1.6-2.3 months; 95% confidence interval). Of 62 patients (34%) who had ascitic fluid analyzed, 36 (58%) had positive cytology. Fifty-one (82%) patients had a serum ascites albumin gradient >= 1, and 11 (18%) had serum ascites albumin gradient < 1. Sixty-four (36%) patients had their ascites managed solely by serial paracenteses. A total of 116 patients required a catheter; of these, 108 (93%) had a Tenckhoff catheter, 4 (3%) a Pleurx catheter, 4 (3%) a pigtail catheter, and 1 (1%) a Denver catheter. Eight (7%) patients required 2 catheters to be placed, and in 6 (5%), Tenckhoff catheters had to be removed. The main observed complications were spontaneous bacterial peritonitis in 7 (11%) managed with paracenteses versus 26 (23%) who had a catheter placed, catheter malfunction in 8 (7%), and acute renal failure in 6 (3%). After ascites development, 79 (44%) patients received active anti-cancer therapy, and 101 (56%) patients were managed with supportive care alone. Conclusions: In patients with PAC who presented with or developed ascites, serial paracenteses and indwelling catheters are common methods used for providing symptomatic relief. The complication rate was higher with indwelling catheters, primarily related to infection (eg, bacterial peritonitis). Overall, ascites has a significantly negative prognostic import with a short median survival.
引用
收藏
页码:360 / 368
页数:9
相关论文
共 50 条
  • [21] Management of adenocarcinoma of the body and tail of the pancreas - Discussion
    Warshaw, AL
    Lillemoe, KD
    Brennan, MF
    ANNALS OF SURGERY, 1996, 223 (05) : 511 - 512
  • [22] Preoperative chemoradiation in the management of adenocarcinoma of the body of the pancreas
    Arnoletti, JP
    Hoffman, JP
    Ross, EA
    Kagan, SA
    Meropol, NJ
    Freedman, G
    Eisenberg, B
    AMERICAN SURGEON, 2002, 68 (04) : 330 - 335
  • [23] RUBELLA - CLINICAL MANIFESTATIONS AND MANAGEMENT
    COOPER, LZ
    ZIRING, PR
    OCKERSE, AB
    FEDUN, BA
    KIELY, B
    KRUGMAN, S
    AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1969, 118 (01): : 18 - &
  • [24] Hepatitis A: Clinical Manifestations and Management
    Jeong, Sook-Hyang
    Lee, Hyo-Suk
    INTERVIROLOGY, 2010, 53 (01) : 15 - 19
  • [25] Arthrogryposis: Clinical manifestations and management
    Ayadi, K.
    Trigui, M.
    Abid, A.
    Cheniour, A.
    Zribi, M.
    Keskes, H.
    ARCHIVES DE PEDIATRIE, 2015, 22 (08): : 830 - 839
  • [26] Clinical manifestations of gout and their management
    van Doornum, S
    Ryan, PFJ
    MEDICAL JOURNAL OF AUSTRALIA, 2000, 172 (10) : 493 - 497
  • [27] Labile iron: Manifestations and clinical implications
    VAN Wyck, DB
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (12): : S107 - S111
  • [28] Clinical Manifestations and Therapeutic Implications of Peritonitis
    Stocker, Felix
    Reim, Daniel
    Hartmann, Daniel
    Novotny, Alexander
    Friess, Helmut
    THERAPEUTISCHE UMSCHAU, 2020, 77 (04) : 171 - 176
  • [29] Therapeutic implications and clinical manifestations of thymoquinone
    Alam, Manzar
    Hasan, Gulam Mustafa
    Ansari, Md Meraj
    Sharma, Rishi
    Yadav, Dharmendra Kumar
    Hassan, Md Imtaiyaz
    PHYTOCHEMISTRY, 2022, 200
  • [30] Clinical Implications of Incomplete Pancreas Divisum
    Kamisawa, Terumi
    Tu, Yuyang
    Egawa, Naoto
    Tsuruta, Kouji
    Okamoto, Aatsutake
    JOURNAL OF THE PANCREAS, 2006, 7 (06): : 625 - 630